BLLN (BillionToOne) ROE % Adjusted to Book Value: 2.03% (As of Mar. 2026)


BLLN BillionToOne Inc BLLN
13 GF Score
Price $122.33
! 5 Warning Signs
View Full Analysis

What is BillionToOne ROE % Adjusted to Book Value?

BillionToOne BLLN +2.04% 13 ROE % Adjusted to Book Value is 2.03% as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

BillionToOne's ROE % for the quarter that ended in Mar. 2026 was 14.58%. BillionToOne's PB Ratio for the quarter that ended in Mar. 2026 was 7.18. BillionToOne's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 2.03%.

BillionToOne ROE % Adjusted to Book Value Related Terms

BillionToOne ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BillionToOne's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne ROE % Adjusted to Book Value Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.84

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial 0.00 0.00 Negative Equity 2.54 2.03

BLLN vs SHC, VCYT, RDNT: ROE % Adjusted to Book Value Comparison

For the Diagnostics & Research subindustry, BillionToOne's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BillionToOne ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BillionToOne's ROE % Adjusted to Book Value falls into.


BLLN
13GF Score
BillionToOne Inc BLLN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne ROE % Adjusted to Book Value Calculation

BillionToOne's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=6.53% / 7.81
=0.84%

BillionToOne's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=14.58% / 7.18
=2.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 2.03% mean?
BillionToOne (BLLN) has a ROE % Adjusted to Book Value of 2.03% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BillionToOne and its competitors.
Is BillionToOne's ROE % Adjusted to Book Value too high?
BillionToOne's current ROE % Adjusted to Book Value is 2.03%. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's ROE % Adjusted to Book Value compare to SHC and VCYT?
BillionToOne's ROE % Adjusted to Book Value of 2.03% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BillionToOne and its competitors. BillionToOne's current ROE % Adjusted to Book Value is 2.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current ROE % Adjusted to Book Value of 2.03%. The current ROE % Adjusted to Book Value is 2.03%. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BillionToOne (BLLN), the current ROE % Adjusted to Book Value is 2.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score

Get the complete analysis for BLLN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.33
Price